An American Academy of Neurology practice advisory finds no apparent clinical use for electroencephalographic theta/beta or frontal power in the evaluation of attention-deficit/hyperactivity disorder, as this testing does not increase diagnostic certainty compared with current clinical criteria.
Sponsoring Organization: American Academy of NeurologyTarget Audience: Neurologists, pediatricians, psychiatrists, psychologists
Background and Objectives
In 2013, the FDA approved marketing of the Neuropsychiatric Electroencephalogram (EEG)-Based Assessment Aid (NEBA) system — which calculates the ratio of the power of EEG theta and beta bands over the Cz electrode — to supplement clinical evaluation for attention-deficit/hyperactivity disorder (ADHD). To determine the clinical utility of NEBA, the authors performed a comprehensive literature search and reviewed 959 abstracts.
Key Points
The authors investigated the following questions:
1. In a patient diagnosed with ADHD, does the combination of clinical examination and EEG theta/beta power ra…
Reviewing Authors
DisclosuresConsultant/Advisory BoardMore Health, Inc.; The Alliance of Medical Companies
Grant/Research SupportNIH Small Business Innovation Research
Leadership Positions in Professional SocietiesSouthern Epilepsy & EEG Society (Treasurer)
DisclosuresConsultant/Advisory BoardMore Health, Inc.; The Alliance of Medical Companies
Grant/Research SupportNIH Small Business Innovation Research
Leadership Positions in Professional SocietiesSouthern Epilepsy & EEG Society (Treasurer)